Seasonal Influenza Market Report 2026

Seasonal Influenza Market Overview

• Seasonal Influenza market size has reached to $9.85 billion in 2025 • Expected to grow to $21.39 billion in 2030 at a compound annual growth rate (CAGR) of 16.7% • Growth Driver: Rise In Respiratory Infections Driving The Market Growth • Market Trend: Advancement In Technology Driving The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Seasonal Influenza Market?

Seasonal influenza, commonly known as the flu, is a contagious respiratory infection caused by influenza viruses that circulate globally, primarily during specific seasons (typically fall and winter in temperate regions). It spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Seasonal influenza leads to widespread illness and can result in serious complications, particularly for vulnerable populations such as the elderly and those with weakened immune systems. The main types of seasonal influenza are influenza A virus, influenza B virus, influenza C virus, and influenza D virus. Influenza A virus is a subtype of the influenza virus that infects humans and various animals and is known to cause seasonal flu outbreaks and pandemics. The route of administration for these treatments includes parenteral, oral, and other routes of administration. It is distributed through various channels such as hospitals, government and institutional supply, pharmacies, and online platforms. It is using various treatment methods, including antivirals, neuraminidase inhibitors, vaccinations, and other treatments.

What Is The Seasonal Influenza Market Growth Forecast?

The seasonal influenza market size is expected to see rapid growth in the next few years. It will grow to $21.39 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to development of universal vaccines, rapid point-of-care diagnostics, digital immunization tracking, public-private vaccination campaigns, supply chain optimization. Major trends in the forecast period include universal flu vaccines, rapid diagnostic tests, home-based vaccination, increasing government immunization programs, pharmaceutical supply chain modernization.

What Is The Driver Of The Seasonal Influenza Market?

The increasing prevalence of respiratory infections is expected to propel the growth of the seasonal influenza market going forward. Respiratory infections are illnesses caused by viruses or bacteria affecting the respiratory system, including the sinuses, throat, airways, or lungs. The increasing prevalence of respiratory infections is driven by air pollution, changing climates, weakened immune responses, and the ease of viral transmission in crowded or poorly ventilated spaces. Seasonal influenza treatment helps prevent or reduce the severity of respiratory infections in several ways, primarily by addressing the influenza virus and managing symptoms that can lead to secondary infections. For instance, in October 2024, according to the UK Health Security Agency, a UK-based government agency, the number of tuberculosis (TB) (a respiratory infection caused by the bacterium Mycobacterium tuberculosis) cases in England experienced a 10.7% year-over-year increase in 2023, rising from 4,380 cases in 2022 to 4,850 cases. Therefore, the rise in respiratory infections will drive the growth of the seasonal influenza industry.

Key Players In The Global Seasonal Influenza Market

Major companies operating in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

Global Seasonal Influenza Market Trends and Insights

Major companies operating in the seasonal influenza market are focusing on advancements in treatment, such as combination vaccines, to enhance immunity by targeting multiple strains of the virus, improving effectiveness, and reducing the need for frequent vaccinations. Combination vaccines protect against multiple diseases or strains with a single injection, reducing the number of shots needed for immunization. For instance, in October 2023, Moderna, Inc., a US-based biotechnology company, announced positive interim Phase 1/2 trial results for mRNA-1083, its investigational combination vaccine targeting both influenza and COVID-19. Designed to enhance compliance, streamline administration, and improve convenience for individuals and healthcare systems, mRNA-1083 is being evaluated for safety and immunogenicity against standard flu vaccines Fluarix (ages 50-64) and Fluzone HD (ages 65-79), as well as compared to the Spikevax booster.

What Are Latest Mergers And Acquisitions In The Seasonal Influenza Market?

In February 2023, Clover Biopharmaceuticals Ltd., a China-based commercial-stage biotechnology company, partnered with Adimmune Corporation. With this partnership, Clover will distribute AdimFlu-S (QIS), the sole imported quadrivalent seasonal influenza vaccine authorized for use in individuals aged three and older in mainland China. Adimmune Corporation is a Taiwan-based company specializing in vaccine development and production.

What Defines the Seasonal Influenza Market?

The seasonal influenza market consists of revenues earned by entities by provide services such flu vaccination services, specialized care for high-risk populations, telemedicine services, and proactive treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The seasonal influenza market consists of sales of medications, diagnostic kits, preventive and supportive products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Seasonal Influenza Market Report 2026?

The seasonal influenza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the seasonal influenza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.